SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Hong Li, Constantine Gatsonis, Dynamic optimal strategy for monitoring disease recurrence, Science China Mathematics, 2012, 55, 8, 1565

    CrossRef

  2. 2
    Andrew J. Vickers, Simon F. Brewster, PSA velocity and doubling time in diagnosis and prognosis of prostate cancer, British Journal of Medical and Surgical Urology, 2012, 5, 4, 162

    CrossRef

  3. 3
    Emmanuel S. Antonarakis, Zhaoyong Feng, Bruce J. Trock, Elizabeth B. Humphreys, Michael A. Carducci, Alan W. Partin, Patrick C. Walsh, Mario A. Eisenberger, The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up, BJU International, 2012, 109, 1
  4. 4
    Yonah Krakowsky, Andrew Loblaw, Laurence Klotz, Prostate Cancer Death of Men Treated With Initial Active Surveillance: Clinical and Biochemical Characteristics, The Journal of Urology, 2010, 184, 1, 131

    CrossRef

  5. 5
    Giampiero Giovacchini, Maria Picchio, Vincenzo Scattoni, Rita Garcia Parra, Alberto Briganti, Luigi Gianolli, Francesco Montorsi, Cristina Messa, PSA doubling time for prediction of [11C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy, European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 6, 1106

    CrossRef

  6. 6
    Kenneth J. Pienta, Critical Appraisal of Prostate-specific Antigen in Prostate Cancer Screening: 20 Years Later, Urology, 2009, 73, 5, S11

    CrossRef

  7. 7
    John M. Fitzpatrick, Eugeniu Banu, Stephane Oudard, Prostate-specific antigen kinetics in localized and advanced prostate cancer, BJU International, 2009, 103, 5
  8. 8
    Michelle L. Ramírez, Eric C. Nelson, Ralph W. deVere White, Primo N. Lara, Christopher P. Evans, Current Applications for Prostate-Specific Antigen Doubling Time, European Urology, 2008, 54, 2, 291

    CrossRef

  9. 9
    Richard G. Stock, Jamie A. Cesaretti, Pamela Unger, Nelson N. Stone, Distant and local recurrence in patients with biochemical failure after prostate brachytherapy, Brachytherapy, 2008, 7, 3, 217

    CrossRef

  10. 10
    Philip M. Arlen, Fernando Bianco, William L. Dahut, Anthony D'Amico, William D. Figg, Stephen J. Freedland, James L. Gulley, Philip W. Kantoff, Michael W. Kattan, Andrew Lee, Meredith M. Regan, Oliver Sartor, Prostate Specific Antigen Working Group Guidelines on Prostate Specific Antigen Doubling Time, The Journal of Urology, 2008, 179, 6, 2181

    CrossRef

  11. 11
    Svend O Freytag, Hans Stricker, James Peabody, Jan Pegg, Dell Paielli, Benjamin Movsas, Kenneth N Barton, Stephen L Brown, Mei Lu, Jae Ho Kim, Five-year Follow-up of Trial of Replication-competent Adenovirus-mediated Suicide Gene Therapy for Treatment of Prostate Cancer, Molecular Therapy, 2007, 15, 3, 636

    CrossRef

  12. 12
    Christopher L. Amling, Biochemical Recurrence after Localized Treatment, Urologic Clinics of North America, 2006, 33, 2, 147

    CrossRef

  13. 13
    SEAMUS J. TEAHAN, LAURENCE H. KLOTZ, Current role of prostate-specific antigen kinetics in managing patients with prostate cancer, BJU International, 2006, 97, 3
  14. 14
    Laurence Klotz, Seamus Teahan, Current Role of PSA Kinetics in the Management of Patients with Prostate Cancer, European Urology Supplements, 2006, 5, 6, 472

    CrossRef

  15. 15
    Timothy J. Daskivich, Meredith M. Regan, William K. Oh, Prostate Specific Antigen Doubling Time Calculation: Not as Easy as 1, 2, 4, The Journal of Urology, 2006, 176, 5, 1927

    CrossRef

  16. 16
    Liang Cheng, Timothy D Jones, Chong-Xian Pan, Ayana Barbarin, John N Eble, Michael O Koch, Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens, Modern Pathology, 2005, 18, 8, 1022

    CrossRef

  17. 17
    Alexander M. Truskinovsky, Alan W. Partin, Martin H. Kroll, Kinetics of tumor growth of prostate carcinoma estimated using prostate-specific antigen, Urology, 2005, 66, 3, 577

    CrossRef

  18. 18
    Eckart Gronau, Marcus Goppelt, Rolf Harzmann, Dorothea Weckermann, Prostate Cancer Relapse after Therapy with Curative Intention: A Diagnostic and Therapeutic Dilemma, Onkologie, 2005, 28, 6-7, 361

    CrossRef

  19. 19
    James A Eastham, Prostate-specific antigen doubling time as a prognostic marker in prostate cancer, Nature Clinical Practice Urology, 2005, 2, 10, 482

    CrossRef

  20. 20
    Alexandra L Hanlon, Eric M Horwitz, Gerald E Hanks, Alan Pollack, Short-term androgen deprivation and PSA doubling time: their association and relationship to disease progression after radiation therapy for prostate cancer, International Journal of Radiation Oncology*Biology*Physics, 2004, 58, 1, 43

    CrossRef

  21. 21
    Glenn M Cannon, Patrick C Walsh, Alan W Partin, Charles R Pound, Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer, Urology, 2003, 62, 2

    CrossRef

  22. 22
    Yoshiyuki Kakehi, Toshiyuki Kamoto, Taizo Shiraishi, Tetsuro Kato, Ken-ichi Tobisu, Koichiro Akakura, Shin Egawa, Osamu Maeda, Yoshiteru Sumiyoshi, Yoichi Arai, Osamu Ogawa, Correlation of Initial PSA Level and Biopsy Features with PSA-Doubling Time in Early Stage Prostate Cancers in Japanese Men, European Urology, 2002, 41, 1, 47

    CrossRef

  23. 23
    Alexandra L Hanlon, Hasmik Diratzouian, Gerald E Hanks, Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer, International Journal of Radiation Oncology*Biology*Physics, 2002, 53, 2, 297

    CrossRef

  24. 24
    N. Salem, Surveillance clinique et biologique après radiothérapie pour cancer de la prostate localisé, Cancer/Radiothérapie, 2002, 6, 3, 159

    CrossRef

  25. 25
    Carlos A Perez, Jeff M Michalski, Mary Ann Lockett, Chemical disease-free survival in localized carcinoma of prostate treated with external beam irradiation: comparison of American Society of Therapeutic Radiology and Oncology Consensus or 1 ng/mL as endpoint, International Journal of Radiation Oncology*Biology*Physics, 2001, 49, 5, 1287

    CrossRef

  26. 26
    Brian J. Miles, Moshe Shalev, Estuardo Aguilar-Cordova, Terry L. Timme, Hon-Man Lee, Guang Yang, Howard L. Adler, Kenneth Kernen, Christina K. Pramudji, Takefumi Satoh, Yehoshua Gdor, Chengzhen Ren, Gustavo Ayala, Thomas M. Wheeler, Edward B. Butler, Dov Kadmon, Timothy C. Thompson, Prostate-Specific Antigen Response and Systemic T Cell Activation AfterIn SituGene Therapy in Prostate Cancer Patients Failing Radiotherapy, Human Gene Therapy, 2001, 12, 16, 1955

    CrossRef

  27. 27
    Richard Choo, Gerrit DeBoer, Lawrence Klotz, Cyril Danjoux, Gerard C Morton, Eileen Rakovitch, Neil Fleshner, Peter Bunting, Linda Kapusta, George Hruby, PSA doubling time of prostate carcinoma managed with watchful observation alone, International Journal of Radiation Oncology*Biology*Physics, 2001, 50, 3, 615

    CrossRef

  28. 28
    John Sylvester, Peter Grimm, John Blasco, Robert Meier, James Spiegel, Charles Heaney, William Cavanagh, The role of androgen ablation in patients with biochemical or local failure after definitive radiation therapy: a survey of practice patterns of urologists and radiation oncologists in the United States, Urology, 2001, 58, 2, 65

    CrossRef

  29. 29
    Aria F Olumi, Jerome P Richie, Delray J Schultz, Anthony V D’Amico, Calculated volume of prostate cancer identifies patients with clinical stage T1c disease at high risk of biochemical recurrence after radical prostatectomy: a preliminary study, Urology, 2000, 56, 2, 273

    CrossRef

  30. 30
    David K Ornstein, Raj S Pruthi, Prostate-specific antigen, Expert Opinion on Pharmacotherapy, 2000, 1, 7, 1399

    CrossRef

  31. 31
    R.S. Pruthi, The dynamics of prostate-specific antigen in benign and malignant diseases of the prostate, BJU International, 2000, 86, 6
  32. 32
    Larry L. Kestin, Frank A. Vicini, Ellen L. Ziaja, Jannifer S. Stromberg, Robert C. Frazier, Alvaro A. Martinez, Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy, Cancer, 1999, 86, 8
  33. 33
    Egawa, Ohori, Iwamura, Kuwao, Baba, Efficacy and limitations of delayed/salvage radiation therapy after radical prostatectomy, BJU International, 1999, 84, 7
  34. 34
    Shin Egawa, Kazumasa Matsumoto, Kazuho Suyama, Masatsugu Iwamura, Sadahito Kuwao, Shiro Baba, Observations of prostate specific antigen doubling time in Japanese patients with nonmetastatic prostate carcinoma, Cancer, 1999, 86, 3
  35. 35
    Frank A Vicini, Larry L Kestin, Alvaro A Martinez, The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer, International Journal of Radiation Oncology*Biology*Physics, 1999, 45, 3, 553

    CrossRef

  36. 36
    D.M Herold, A.L Hanlon, B Movsas, G.E Hanks, Age-Related Prostate Cancer Metastases, Urology, 1998, 51, 6, 985

    CrossRef

  37. 37
    GLENN S. GERBER, HEATHER L. GORNIK, EVAN R. GOLDFISCHER, GERALD W. CHODAK, DANIEL B. RUKSTALIS, EVALUATION OF CHANGES IN PROSTATE SPECIFIC ANTIGEN IN CLINICALLY LOCALIZED PROSTATE CANCER MANAGED WITHOUT INITIAL THERAPY, The Journal of Urology, 1998, 159, 4, 1243

    CrossRef

  38. 38
    GLENN S. GERBER, HEATHER L. GORNIK, EVAN R. GOLDFISCHER, GERALD W. CHODAK, DANIEL B. RUKSTALIS, EVALUATION OF CHANGES IN PROSTATE SPECIFIC ANTIGEN IN CLINICALLY LOCALIZED PROSTATE CANCER MANAGED WITHOUT INITIAL THERAPY, The Journal of Urology, 1998, 1243

    CrossRef

  39. 39
    DAISAKU HIRANO, PRIYA N. WERAHERA, E. DAVID CRAWFORD, M. SCOTT LUCIA, EDWARD P. DeANTONI, GARY J. MILLER, MORPHOLOGICAL ANALYSIS AND CLASSIFICATION OF LATENT PROSTATE CANCER USING A 3-DIMENSIONAL COMPUTER ALGORITHM, The Journal of Urology, 1998, 1265

    CrossRef

  40. 40
    DAISAKU HIRANO, PRIYA N. WERAHERA, E. DAVID CRAWFORD, M. SCOTT LUCIA, EDWARD P. DeANTONI, GARY J. MILLER, MORPHOLOGICAL ANALYSIS AND CLASSIFICATION OF LATENT PROSTATE CANCER USING A 3-DIMENSIONAL COMPUTER ALGORITHM: ANALYSIS OF TUMOR VOLUME, GRADE, TUMOR DOUBLING TIME AND LIFE EXPECTANCY, The Journal of Urology, 1998, 159, 4, 1265

    CrossRef

  41. 41
    M. Reni, A. Bolognesi, Prognostic value of prostate specific antigen before, during and after radiotherapy, Cancer Treatment Reviews, 1998, 24, 2, 91

    CrossRef

  42. 42
    Deborah A. Kuban, Anas M. El-Mahdi, Paul F. Schellhammer, PSA for outcome prediction and posttreatment evaluation following radiation for prostate cancer: Do we know how to use it?, Seminars in Radiation Oncology, 1998, 8, 2, 72

    CrossRef

  43. 43
    J.M Crook, E Choan, G.A Perry, S Robertson, B.A Esche, Serum Prostate-Specific Antigen Profile Following Radiotherapy for Prostate Cancer: Implications for Patterns of Failure and Definition of Cure, Urology, 1998, 51, 4, 566

    CrossRef

  44. 44
    Peter A. S. Johnstone, Curt R. Powell, Robert Riffenburgh, Kelly J. Bethel, Christopher J. Kane, The fate of 10-year clinically recurrence-free survivors after definitive radiotherapy for T1–3N0M0 Prostate Cancer , Radiation Oncology Investigations, 1998, 6, 2
  45. 45
    Christopher C Parker, David P Dearnaley, The management of PSA failure after radical radiotherapy for localized prostate cancer, Radiotherapy and Oncology, 1998, 49, 2, 103

    CrossRef

  46. 46
    Anthony V. D'Amico, Hyunil Chang, Edward Holupka, Andrew Renshaw, April Desjarden, Minghui Chen, Kevin R. Loughlin, Jerome P. Richie, Calculated prostate cancer volume: The optimal predictor of actual cancer volume and pathologic stage, Urology, 1997, 49, 3, 385

    CrossRef

  47. 47
    Karin M.G. Haustermans, Ingrid Hofland, Hein Van Poppel, Raymond Oyen, Wim Van de Voorde, Adrian C. Begg, Jack F. Fowler, Cell kinetic measurements in prostate cancer, International Journal of Radiation Oncology*Biology*Physics, 1997, 37, 5, 1067

    CrossRef

  48. 48
    S. Egawa, K. Matsumoto, M. Iwamura, T. Uchida, S. Kuwao, K. Koshiba, Impact of Life Expectancy and Tumor Doubling Time on the Clinical Significance of Prostate Cancer in Japan, Japanese Journal of Clinical Oncology, 1997, 27, 6, 394

    CrossRef

  49. 49
    Carolyn I. Sartor, Myla H. Strawderman, Xi-Hong Lin, Katherine E. Kish, Patrick W. McLaughlin, Howard M. Sandler, Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy, International Journal of Radiation Oncology*Biology*Physics, 1997, 38, 5, 941

    CrossRef

  50. 50
    Robert A. Badalament, Duke K. Bahn, Fred Lee, Is radical prostatectomy primarily a surgical debulking procedure?, Urologic Oncology: Seminars and Original Investigations, 1996, 2, 3, 88

    CrossRef

  51. 51
    Gerald E. Hanks, Alexandra L. Hanlon, W.Robert Lee, Anne Slivjak, Timothy E. Schultheiss, Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior, International Journal of Radiation Oncology*Biology*Physics, 1996, 34, 3, 549

    CrossRef

  52. 52
    Anthony V. D'Amico, Kathleen J. Propert, Prostate cancer volume adds significantly to prostate-specific antigen in the prediction of early biochemical failure after external beam radiation therapy, International Journal of Radiation Oncology*Biology*Physics, 1996, 35, 2, 273

    CrossRef

  53. 53
    B Chauvet, T Jacob, JL Davin, C Berger, P Vincent, F Reboul, Prostate specific antigen (PSA): impact d'un marqueur sérique sur la prise en charge diagnostique et thérapeutique des cancers de prostate, Bulletin du Cancer/Radiothérapie, 1996, 83, 4, 334

    CrossRef

  54. 54
    Y. Kubota, H. Yanai, I. Sasagawa, H. Suzuki, T. Nakada, O. Sugano, Prostate-specific antigen in patients with relapsed prostate cancer following endocrine treatment, International Urology and Nephrology, 1996, 28, 3, 349

    CrossRef

  55. 55
    Jack F. Fowler, Mark A. Ritter, A rationale for fractionation for slowly proliferating tumors such as prostatic adenocarcinoma, International Journal of Radiation Oncology*Biology*Physics, 1995, 32, 2, 521

    CrossRef

  56. 56
    Byan D. Leibman, ÖZdal Dillioglugil, Thomas M. Wheeler, Peter T. Scardino, Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level, Cancer, 1995, 76, 12
  57. 57
    Steven L. Hancock, Richard S. Cox, Malcolm A. Bagshaw, Prostate Specific Antigen After Radiotherapy for Prostate Cancer, The Journal of Urology, 1995, 1412

    CrossRef

  58. 58
    Steven L. Hancock, Richard S. Cox, Malcolm A. Bagshaw, Prostate Specific Antigen After Radiotherapy for Prostate Cancer: A Reevaluation of Long-Term Biochemical Control and Kinetics of Recurrence in Patients Treated at Stanford University, The Journal of Urology, 1995, 154, 4, 1412

    CrossRef

  59. 59
    Alan Pollack, Gunar K. Zagars, Vivek S. Kavadi, Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer, Cancer, 1994, 74, 2
  60. 60
    Gerald E. Hanks, Carlos A. Perez, M. Kozar, Sucha O. Asbell, Miljenko V. Pilepich, Thomas F. Pajak, PSA confirmation of cure at 10 years of T1B, T2, N0, M0 prostate cancer patients treated in RTOG protocol 7706 with external beam irradiation, International Journal of Radiation Oncology*Biology*Physics, 1994, 30, 2, 289

    CrossRef

  61. 61
    Alan Pollack, Gunar K. Zagars, Adel K. El-Naggar, Nicholas H.A. Terry, Relationship of tumor DNA-ploidy toserum prostate-specific antigen doubling time after radiotherapy for prostate cancer, Urology, 1994, 44, 5, 711

    CrossRef